Experimental vaccine takes on tough pancreatic cancer
NCT ID NCT07231094
First seen Nov 17, 2025 · Last updated Jun 21, 2026 · Updated 31 times
Summary
This early-phase trial will test a new tumor vaccine (SapDM275) combined with standard chemotherapy in 13 people with metastatic pancreatic cancer who haven't had prior treatment. The vaccine aims to train the immune system to attack stress proteins on cancer cells. The main goal is to check safety, with some early looks at tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Third Xiangya Hospital of Central South University
Hunan, Changsha, 410000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SapDM275 tumor vaccine
What this could lead to
If it works, this could point toward a new treatment option for metastatic pancreatic cancer by helping the immune system attack tumors.
What could go wrong
This is a very early, small trial (13 people) focused on safety, not proof of effectiveness. The vaccine may not shrink tumors or improve survival, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.